Month: November 2022

On March 22, 2011, Ryono, Denis E.; Cheng, Peter T. W.; Bolton, Scott A.; Chen, Sean; Shi, Yan; Meng, Wei; Tino, Joseph A. published a patent.Computed Properties of 97859-49-9 The title of the patent was Preparation of phosphonate and phosphinate pyrazolylamide glucokinase activators. And the patent contained the following:

Pyrazoloamides are provided which are phosphonate and phosphinate glucokinase activators that are useful in treating diabetes and related diseases and have the structure I (circle = pyrazoyl ring; R4 = -(CH2)n-Z-(CH2)m-PO(OR7)(OR8), -(CH2)nZ-(CH2)m-PO(OR7)R9, or -(CH2)nZ-(CH2)m-PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R3(CH2)s, wherein R3 is aryl , s is 0, X is a bond; and n, Z, m, R4, R5, R6, and R7 are as defined herein; or a pharmaceutically acceptable salt thereof). The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Computed Properties of 97859-49-9

The Article related to phosphonate phosphinate pyrazolylamide glucokinase activator preparation, Organometallic and Organometalloidal Compounds: Phosphorus Compounds and other aspects.Computed Properties of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On January 31, 2013, Hoffmann, Matthias; Bischoff, Daniel; Dahmann, Georg; Klicic, Jasna; Schaenzle, Gerhard; Wollin, Stefan Ludwig Michael; Convers-Reignier, Serge Gaston; East, Stephen Peter; Marlin, Frederic Jacques; McCarthy, Clive; Scott, John published a patent.Synthetic Route of 97859-49-9 The title of the patent was Preparation of substituted quinolines as Syk inhibitors for therapy. And the patent contained the following:

The invention relates to substituted quinolines of formula I (wherein R1 is a (un)substituted C1-6-alkyl; R2 is halogen, (un)substituted Ph, (un)substituted five- or six-membered monocyclic heteroaryl, or (un)substituted bicyclic ring system), and their use as Syk inhibitors in the preparation of medicaments for the treatment of disease such as asthma, COPD, allergic rhinitis, allergic dermatitis and rheumatoid arthritis. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting intermediates 7-phenylquinolin-5-ol and (R)-4-((S)-1-hydroxyethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one and deprotecting the compound formed. The examples compounds were tested in a human Syk kinase inhibition assay, and had IC50 values ≤ 1 μmol. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Synthetic Route of 97859-49-9

The Article related to preparation quinoline syk inhibitor therapy, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Synthetic Route of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On October 8, 2015, Anderson, David Randolph; Bunnage, Mark Edward; Curran, Kevin Joseph; Dehnhardt, Christoph Martin; Gavrin, Lori Krim; Goldberg, Joel Adam; Han, Seungil; Hepworth, David; Huang, Horng-Chih; Lee, Arthur; Lee, Katherine Lin; Lovering, Frank Eldridge; Lowe, Michael Dennis; Mathias, John Paul; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy Susan; Saiah, Eddine; Strohbach, Joseph Walter; Trzupek, John David; Vargas, Richard; Wang, Xiaolun; Wright, Stephen Wayne; Zapf, Christoph Wolfgang published a patent.Product Details of 97859-49-9 The title of the patent was Bicyclic-fused heteroaryl or aryl compounds as IRAK4 inhibitors and their preparation. And the patent contained the following:

Compounds of formula I, tautomers and pharmaceutically acceptable salts of the compounds are disclosed. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. Compounds of formula I wherein X, X’ and Y are independently CR8′, N and N+O-; provided at at least one of X, X’ and Y is N or N+O- and no more than one of X, X’ and Y is N+O-; R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R2 is (un)substituted C0-3 alkyl-C3-10 cycloalkyl, (un)substituted C0-3 alkyl-C6-12 aryl, (un)substituted C0-3 alkyl-heteroaryl; R6 is CONH2 and derivatives, CO2H and derivatives, and CN; each R8 is independently H, halo, CN, OH and derivatives, SH and derivatives, etc.; R8′ is H, D, halo, CN, etc.; and pharmaceutically acceptable salts and tautomers, thereof are claimed. Example compound II was prepared by enzyme-mediated epimerization of 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide followed by hydrolysis. The invention compounds were evaluated for their IRAK4 inhibitory activity (some data given). The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to bicyclic heteroaryl aryl compound preparation irak4 inhibitor, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

Burkhardt, Immo; Lauterbach, Lukas; Brock, Nelson L.; Dickschat, Jeroen S. published an article in 2017, the title of the article was Chemical differentiation of three DMSP lyases from the marine Roseobacter group.Computed Properties of 168297-86-7 And the article contains the following content:

Dimethylsulfoniopropionate (DMSP) catabolism of marine bacteria plays an important role in marine and global ecol. The genome of Ruegeria pomeroyi DSS-3, a model organism from the Roseobacter group, harbors no less than three genes for different DMSP lyases (DddW, DddP and DddQ) that catalyze the degradation of DMSP to di-Me sulfide (DMS) and acrylate. Despite their apparent similar function these enzymes show no significant overall sequence identity. In this work DddQ and DddW from R. pomeroyi and the DddP homolog from Phaeobacter inhibens DSM 17395 were functionally characterized and their substrate scope was tested using several synthetic DMSP analogs. Comparative kinetic assays revealed differences in the conversion of DMSP and its analogs in terms of selectivity and overall velocity, giving addnl. insights into the mol. mechanisms of DMSP lyases and into their putatively different biol. functions. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to ruegeria dmsp lyase isoenzyme recognition substrate analog preparation kinetics, Enzymes: Substrates-Cofactors-Inhibitors-Activators-Coenzymes-Products and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 28, 2001, Madar, D. J.; Kopecka, H.; Pireh, D.; Pease, J.; Pliushchev, M.; Sciotti, R. J.; Wiedeman, P. E.; Djuric, S. W. published an article.HPLC of Formula: 97859-49-9 The title of the article was Synthesis of N-arylated oxazolidinones via a palladium catalyzed cross coupling reaction. Application to the synthesis of the antibacterial agent Dup-721. And the article contained the following:

A method for the intermol. coupling of aryl bromides and oxazolidinones is described. Application to intermediates useful for the preparation of a known class of antibacterial agent and the synthesis of the known antibacterial oxazolidinone Dup-721 are described. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).HPLC of Formula: 97859-49-9

The Article related to arylated oxazolidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.HPLC of Formula: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On October 4, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Application of 97859-49-9 The title of the patent was Oxazolidinone compounds as antibiotics and process of preparation. And the patent contained the following:

The disclosure relates to compounds of formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The disclosure also relates to the synthesis and characterization of aforementioned substances. Compounds of formula I wherein A is absent and CH2; B is CH2 and CH2CH2; X1 is N and CR4; X2 is N and CR5; Y1 and Y2 are independently N and CR7; Z1 is O, S, NH and CH2; R1 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-6 cycloalkyl, etc.; R2 is H, halo, OH, CN, C1-6 alkoxy, etc.; R3 is H, F, C1-4 alkoxy, etc.; R4 is H, C1-4 alkoxy, C1-6 haloalkyl, etc.; R5 is H, CN, (un)substituted C1-6 alkyl, CO2H, etc.; R6 is H, C1-6 alkyl and C1-6 alkoxy; R7 is H, halo, CN, C1-6 alkoxy, etc.; and stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are claimed. Example compound II was prepared by reductive alkylation of 6-(5-(2-aminoethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with 2-(4-methyl-3,6-dioxo-4,6-dihydropyrido[2,3-b]pyrazin-5(3H)-yl)acetaldehyde. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited MIC values in the range of 0.06μg/mL to 0.5μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Application of 97859-49-9

The Article related to oxazolidinone preparation antibiotic, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Application of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On October 3, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Electric Literature of 97859-49-9 The title of the patent was Oxazolidinone compounds as antibiotics and process of preparation. And the patent contained the following:

The disclosure relates to compounds of formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The disclosure also relates to the synthesis and characterization of aforementioned substances. Compounds of formula I wherein A is absent and CH2; B is CH2 and CH2CH2; X1 is N and CR4; X2 is N and CR5; Y1 and Y2 are independently N and CR7; Z1 is O, S, NH and CH2; R1 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-6 cycloalkyl, etc.; R2 is H, halo, OH, CN, C1-6 alkoxy, etc.; R3 is H, F, C1-4 alkoxy, etc.; R4 is H, C1-4 alkoxy, C1-6 haloalkyl, etc.; R5 is H, CN, (un)substituted C1-6 alkyl, CO2H, etc.; R6 is H, C1-6 alkyl and C1-6 alkoxy; R7 is H, halo, CN, C1-6 alkoxy, etc.; and stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are claimed. Example compound II was prepared by reductive alkylation of 6-(5-(2-aminoethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with 2-(4-methyl-3,6-dioxo-4,6-dihydropyrido[2,3-b]pyrazin-5(3H)-yl)acetaldehyde. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited MIC values in the range of 0.06μg/mL to 0.5μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Electric Literature of 97859-49-9

The Article related to oxazolidinone preparation antibiotic, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Electric Literature of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 29, 2001, Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Ni, Zhi-jie; Gordon, Eric published a patent.Formula: C4H7NO3 The title of the patent was Preparation of oxazolidinones as bactericides. And the patent contained the following:

Title compounds [e.g., I; R = H; R1 = SR11, CONR7R8, etc.; R7,R8,R11 = H, alkyl, (hetero)aryl, etc.] were prepared Thus, 3,4-F(Me3CO2C)C6H3NHCO2CH2Ph (preparation given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in several steps to I (R = resin, R1 = CO2C6F5) which was amidated by morpholine to give, after resin cleavage, I (R = H, R1 = CONHR8, R8 = morpholino). Data for biol. activity of I were given. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Formula: C4H7NO3

The Article related to oxazolidinone preparation bactericide, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On March 24, 2005, Hagen, Susan Elizabeth; Josyula, Vara Prasad Venkata Nagendra published a patent.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of substituted quinolones and derivatives thereof as antibacterial agents. And the patent contained the following:

Title compounds I [Z2 = aminocarbonyl, carbonylamino, CN; either D = N, E = C, F = CH or D = CH, E = N, F = CH2 if — is absent; J, K, Q = (un)substituted alkyl, N with provisions; n = 0-2; at least one of W, X, Y = NP; P = substituted quinolone] are prepared For instance, II is prepared from 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid boron difluoride chelate and N-[2-oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide to give an intermediate borate ester which is converted to the final product upon treatment with Et3N, water at reflux for 18 h. II has MIC 1 μg/mL against E. Faecalis and 0.06 μg/mL against S. aureus. I are useful for the treatment of bacterial infections. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to antibacterial agent quinolone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 31, 1995, Danielmeier, Karsten; Steckhan, Eberhard published an article.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was Efficient pathways to (R)- and (S)-5-hydroxymethyl-2-oxazolidinone and some derivatives. And the article contained the following:

Two new syntheses of enantiomerically pure (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been developed starting with D-mannitol, L-ascorbic acid and (R)- or (S)-malic acid. (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been used to synthesize some new homochiral 2-oxazolidinone derivatives The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to oxazolidinone derivative enantiomerically pure, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem